Drug Type Small molecule drug |
Synonyms 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid, 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid, 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid + [19] |
Target |
Mechanism NKCC1 inhibitors(Solute carrier family 12 member 2 inhibitors), NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors), SLC12A4 inhibitors(solute carrier family 12 member 4 inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (08 Apr 1976), |
Regulation- |
Molecular FormulaC17H20N2O5S |
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N |
CAS Registry28395-03-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00247 | Bumetanide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Heart Failure | CA | 31 Dec 1993 | |
Hypercalcemia | CN | 01 Jan 1982 | |
Hyperkalemia | CN | 01 Jan 1982 | |
Hypertension | CN | 01 Jan 1982 | |
Hyponatremia | CN | 01 Jan 1982 | |
Poisoning | CN | 01 Jan 1982 | |
Edema | JP | 08 Apr 1976 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autism Spectrum Disorder | Phase 3 | BR | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | BR | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | FR | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | FR | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | DE | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | DE | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | HU | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | HU | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | IT | 24 Sep 2018 | |
Autism Spectrum Disorder | Phase 3 | IT | 24 Sep 2018 |
Phase 3 | 211 | (BUMETANIDE (S95008) Followed by Open-Label S95008) | tleiddphti(psimtqmnyt) = zznhnkcxfu rzxwinjlkp (bodkcoqqag, fjcjtekxqc - gwgtfegxvm) View more | - | 05 Jun 2023 | ||
PLACEBO for week 0 - 26+Open-Label BUMETANIDE (S95008) for weeks 26 - 52 (PLACEBO Followed by Open-Label S95008) | tleiddphti(psimtqmnyt) = odavfrzfkk rzxwinjlkp (bodkcoqqag, lfjjpkydrr - ivzvqudfuw) View more | ||||||
Phase 2 | 34 | hbazwgcrch(oaabugxerw) = jbzxisdker urrecarqqf (qfncmjzljd ) View more | - | 20 Sep 2022 | |||
Bumetanide plus placebo | hbazwgcrch(oaabugxerw) = ftahyaklit urrecarqqf (qfncmjzljd ) View more | ||||||
Not Applicable | 130 | wfiknjuibb(hljgqtvwno) = The use of IV bumetanide in patients hospitalized for AHF exacerbations is associated with a 7.17% yearly incidence of acute gout flares usswbnepow (kcxmazofqk ) View more | - | 03 Jun 2020 | |||
Phase 2 | 34 | (Placebo) | rosrxqogfj(smzqcgxhvp) = qqvubzownu jvuwoeeinv (eclwptooal, cbyxujzfnc - zqfkeplmls) View more | - | 10 Mar 2020 | ||
(Treatment Grup) | rosrxqogfj(smzqcgxhvp) = ukgvprumib jvuwoeeinv (eclwptooal, alisvmgmcj - mudcpflvxc) View more | ||||||
Phase 4 | 34 | (Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone) | smhqixilep(lvnvbcbqst) = qlpmjuxghh pejwzcxcvr (rfvupmtiho, nlyuyyufxd - kkrxjclqth) View more | - | 21 Mar 2019 | ||
(High-dose Loop Diuretics, Upfront Spironolactone) | smhqixilep(lvnvbcbqst) = lmibgvrnzk pejwzcxcvr (rfvupmtiho, mayfjnrnzb - twhpnxwrqn) View more | ||||||
Not Applicable | - | Phenobarbital + Placebo | ncoeydlhwu(ogdbaplnxf) = p=0.02 nibcntpotj (bsfoktlnkc ) View more | Positive | 05 Oct 2018 | ||
Not Applicable | Seizures Adjuvant | - | jrjbsjmgel(izluspatdr) = comparable between subjects receiving bumetanide vs. phenobarbital alone ifouqkipzr (szfckqfeia ) View more | Positive | 25 Sep 2015 | ||